The drugmaker said the analyses of the individual mutations present in the Omicron variant indicate “that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity.”

Further analyses are ongoing, the company said, adding that there was no direct data testing Omicron’s resistance to immunity gained from vaccines and monoclonal antibodies.